|Bid||46.62 x 800|
|Ask||46.55 x 800|
|Day's Range||46.31 - 47.12|
|52 Week Range||38.20 - 58.83|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||0.96 (2.07%)|
|Ex-Dividend Date||Jun 03, 2021|
|1y Target Est||54.13|
The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel. The justices turned away AbbVie's appeal and left intact the lower court's finding that its 2011 complaint against Perrigo was brought solely to delay Perrigo's proposed generic version of AndroGel. The Philadelphia-based 3rd U.S. Circuit Court of Appeals last year threw out a federal judge's order requiring AbbVie and partner Besins Pharmaceuticals to disgorge $448 million in profits to the Federal Trade Commission, but found that the judge had correctly determined that they had violated antitrust law.
We last reviewed the charts of Perrigo Corp. on April 9, 2020. In the daily bar chart of PRGO, below, we can see that the shares broke a downtrend line and have rallied above the 50-day and 200-day moving average lines. The daily On-Balance-Volume (OBV) line has been moving higher the past three months to support and confirm the price gains.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.